SpringWorks Therapeutics a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. Co.'s product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Co.'s second product candidate is mirdametinib, an oral, small molecule MEK inhibitor initially in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas. We show 19 historical shares outstanding datapoints in our SWTX shares outstanding history coverage, used to compute SWTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SWTX market cap history over the course of time is important for investors
interested in comparing SWTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SWTX versus a peer is one thing; comparing
SWTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SWTX can fluctuate over the course of history.
With this page we aim to empower investors researching SWTX by allowing them to research the SWTX market cap history. |
Free SWTX Email Alerts:
Video: The Importance of Market Cap
